ANTIBODIES AGAINST HAEMOPHILUS INFLUENZAE TYPE B (HIB) BEFORE AND AFTER A BOOSTER DOSE OF THE CARRIER PROTEIN, TETANUS TOXOID, IN ALREADY PRIMED CHILDREN

B.A. Claesson, T. Lagergard, J. Taranger, B Trollfors.

Departments of Infectious Diseases, Medical Microbiology and Immunology, and Pediatrics, Goteborg University, Goteborg, Sweden

Background: After the introduction of Haemophilus influenzae type b (Hib) conjugate vaccines for infants there is a need to follow Hib antibody levels to confirm that children are protected to the age when "natural immunity" against invasive Hib infections has been acquired. There has also been discussed if vaccination with the carrier protein could increase antibodies against Hib in already primed children.  

Methods: In 53 of 84 Swedish children immunized with 3 doses of a Hib-tetanus toxoid conjugate vaccine (Hib-T) (NICHD, NIH, USA) in infancy, serum samples were obtained before and one month after a booster dose of Vaccine against Diphtheria and Tetanus(SBL Vaccin AB, Sweden). Antibodies against Hib were measured with ELISA.

Results:  Table. Serum antibodies against Hib in 10-year-old children (n=53) vaccinated in infancy with Hib-T before and after a booster dose of the carrier protein. Geometric mean (GM) antibody concentrations (microgram/ml), range,  and proportions of children(%)with antibodies above 0.15 and 1.0 microgram/ml.

                                     Above

            GM       Range          0.15          1.0

________________________________________________

Pre      4.16     0.32 - 545.2     100        83        

Post     4.30     0.39 - 749.0     100        87

________________________________________________

Conclusion: Children immunized with 3 doses of a Hib-tetanus toxoid vaccine in infancy still had high Hib antibody levels at 10 years of age. A booster dose of the carrier protein, tetanus toxoid, did not further increase Hib antibodies.